Mabion reduced its loss in Q1 2026, reactivates MabionCD20 project and enters contract conversion phase

Phone: +48 42 207 78 90 Email address: [email protected] www.mabion.eu 1 Poland, Konstantynów Łódzki, 19th May 2026 Press release Mabion reduced its loss in Q1 2026, reactivates MabionCD20 project and enters contract conversion phase Mabion, a leading Polish biotechnology company, has published its financial results for Q1 2026, during which it reduced losses across key financial metrics and maintained strong cost discipline Revenues in Q1 2026 increased by 68% to PLN 4.6 million, significantly driven by the provision of CDMO services to clients: Novavax from the US, IBMP from Brazil, Novalgen from the UK and WPD from Poland Operating costs in Q1 2026 were reduced by 16.9% year-over-year to 14.0 million PLN, and cash on hand as of the end of March 2026 amounted to 6.6 million PLN, including the first payments from bridge financing totaling nearly 40 million PLN, which Mabion secured over the past few months The current level of cash , together with loans being drawn down in stages , ensures the Company’s operational continuity and is expected to enable it to reach the EBITDA break-even point by the end of 2026 In 2026 , Mabion is focusing on identifying projects it can pursue under a co -development model , expanding its operations to include innovative products that constitute intellectual property and allow for the sharing of risks, costs, and future profits with clients After the balance sheet date, Mabion signed a letter of intent (LOI) with the French company Oddifact SAS for the joint development of the drug MabionCD20 in the new area of orphan diseases; this collaboration is part of the implementation of the Company’s Strategy for 2025–2030 The signed LOI provides for the joint preparation of materials to secure financing for the development of MabionCD20, as well as participation in meetings with regulatory authorities through September 30 of this year; the next phase will specify further steps, including the material and financial contributions of both parties, as reflected in a collaboration agreement and relevant SOWs Financial Results In Q1 2026, Mabion generated revenue of PLN 4.6 million (+68% y/y), significantly driven by CDMO services provided to the U.S. client Novavax, as well as projects for: Instituto De Biologia Molecular Do Parana (IBMP), Novalgen and WPD Pharmaceuticals. All services provided by Mabion are being delivered on schedule, gradually building trust and global recognition for the company. In the first quarter of 2026, Mabion maintained strict cost discipline, which resulted in a significant reduction in losses across key profitability metrics: an operating loss of PLN 9.2 million (a decrease of PLN 4.9 million year-over-year), PLN 7.0 million in EBITDA loss (a reduction of PLN 4.7 million y/y), and PLN 9.7 million in net loss (a reduction of PLN 5.5 million y/y). Operating costs amounted to 14.0 million PLN, down 16.9% year-over-year. Capital expenditures (Capex) remained at a minimal level of 0.04 million PLN, in line with the Company’s current needs. Cash and cash equivalents as of the end of March 2026 amounted to PLN 6.6 million, including a portion of the bridge financing secured in recent months in the amount of nearly PLN 40 million. This amount consists of loans from the majority shareholder – Twiti Investments (up to PLN 18 million) – as well as from ACRX Investments (up to PLN 6 million) and the Japanese strategic investor CBC Co., Ltd. (up to EUR 3.1 million). These funds, released in stages, ensure the Company’s Phone: +48 42 207 78 90 Email address: [email protected] www.mabion.eu 2 operational continuity and are intended to enable it to reach the EBITDA break -even point by the end of 2026. All three loan agreements provide the right to convert the loans into Company shares. In Q1 2025, the Company secured orders for analytical services from existing clients worth over PLN 7.5 million, a result significantly better than the pace observed in the same period last year. As of May 19, 2026, the total value of Mabion active offers stands at USD 258 million, including USD 53 million in offers with a high probability of conversion. “In the first quarter of 2026, we consistently implemented the objectives of our Strategy, focusing both on further cost optimization and improving operational efficiency, as well as on developing promising projects with higher added value. During the reporting period, we reduced our losses while maintaining cost discipline and ensuring the Company’s operational continuity. Our current cash position, supported by loans being drawn down in stages, creates the conditions for Mabion to continue growing its bus iness. We are now entering a period of decision-making regarding selected contracts from our portfolio of active offers with a high probability of conversion , totaling USD 53 million, and at the same time we are reactivating the MabionCD20 project, which we intend to implement under a new co -development model with our French partner Oddifact SAS” – said Gregor Kawaletz, Chief Executive Officer of Mabion S.A. Mabion is back – reactivation of the CD20 project In the first quarter of 2026, Mabion continued to implement its 2025–2030 Strategy, focusing on building its order portfolio and expanding its business model to include co -development partnerships. The Company is consciously moving away from the traditional, simple fee -for-service CDMO model toward advanced collaboration, in which Mabion shares development risks and costs with clients, but also shares the profits from product commercialization. This model allows the Company not only to optimally utilize the production capacity of its facility in Konstantynów Łódzki, but also to build long-term value through co-ownership of the manufactured drugs and the associated intellectual property. After the balance sheet date, the Company announced a plan to utilize its scientific assets in the MabionCD20 project as a component for the creation of innovative drugs. To this end, in May 2026, Mabion signed a letter of intent with the French biotechnology company Oddifact SAS regarding a partnership to reactivate the MabionCD20 project, which was originally developed as a biosimilar. Under the new strategy, Mabion will seek to develop and register MabionCD20 as an innovative therapy for orphan diseases. The partnership with Oddifact, a company that uses artificial intelli gence (AI) to identify new therapeutic applications, aims to accelerate regulatory processes with the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). The letter of intent signed between Mabion and Oddifact SAS outlines a two -phase collaboration process. In the first phase, which the parties intend to complete by September 30, 2026, the Mabion and Oddifact teams will jointly prepare a regulatory strategy and materials for potential investors and regulatory a uthorities, including the U.S. Food and Drug Administration (FDA). The second phase involves entering into a binding Cooperation Agreement by the end of 2026, which will define the final material and financial contributions of both parties to the drug’s de velopment and commercialization. A recent visit by representatives of the French partner to Mabion headquarters confirmed the strong synergy between the two teams – Oddifact, which transforms off -label uses of existing drugs into authorized therapies for patients suffering from rare diseases , and Mabion, which in recent years has developed a CD20 monoclonal antibody as a biosimilar candidate relative to MabThera and Rituxan and has an in-depth understanding of this molecule. “Together with our business partners from France, we had the opportunity to hold a very productive kick -off meeting and workshops that brought together teams with years of experience in modern technologies and innovative thinking. The meeting resulted in an exchange of ideas, incredible energy, strong t eam synergy, and most importantly tangible progress toward achieving our strategic and project goals. It is inspiring to see how unique know-how and groundbreaking innovations work hand in hand, creating the n ext chapter in Mabion history through the reactivation of the MabionCD20 project . We face a series of challenges ahead, yet our course of action is clearly defined “ – said Joaquin Santos Benito, Chief Transformation Officer of Mabion S.A. Phone: +48 42 207 78 90 Email address: [email protected] www.mabion.eu 3 MabionCD20 is a monoclonal antibody developed by the Company as a biosimilar candidate for MabThera and Rituxan (used, among other things, in the treatment of lymphoma and rheumatoid arthritis). The collaboration with Oddifact SAS represents a breakthrough opportunity to restart this project and fully commercialize it under a new framework. By leveraging the scientific knowledge accumulated over the years and advanced process data, Mabion intends to bring CD20 to market under a new model as an innovative therapy addressing unmet medical needs in niche areas of rare diseases. Furthermore, Mabion is consistently pursuing a strategy to enter the antibody -drug conjugate (ADC) segment, which is identified as one of the fastest-growing areas in the biologics sector. These activities form part of the innovation pillar of the 2025–2030 Strategy and aim to build a portfolio of high -value-added products based on a co -development model and proprietary intellectual property. A key element of this expansion is the collaboration with Celon Pharma S.A., where Mabion serves as the prime contra ctor responsible for protein development and analytics, with a potential option for subsequent licensing of the conjugation technology. The Company is also conducting advanced work for WPD Pharmaceuticals on the development of analytical methods for an ADC drug candidate, which is a recombinant protein conjugated with a cytotoxic substance. An important element of building Mabion global recognition and actively securing new contracts is the Company’s participation in major international industry events. In line with its Strategy 2025–2030, which aims to increase its presence in global markets and promote its exp ertise in biologics and the ADC segment, Mabion, together with WPD Pharmaceuticals, will participate in the prestigious BIO International Convention 2026, which will take place June 22–25 in San Diego, USA. The joint presence of both entities at the national pavilion organized by the Polish Investment and Trade Agency (PAIH), located in Hall A at Booth No. 1411, is a natural continuation of their deepening technological and business cooperation. “The BIO International Convention in San Diego is a key forum for Mabion to directly showcase our CDMO offerings and co-development model on a global scale. Sharing a booth with WPD Pharmaceuticals at the stand organized by PAIH is an excellent opportunity to demonstrate to the market that we are ready for the most demanding technological challenges, combining our analytical excellence with competitive infrastructure in the European Union” – adds Detlef Behrens, Chief Business Affairs Officer of Mabion S.A. Contact for media and individual investors Michał Wierzchowski +48 531 613 067 +48 22 440 14 40 [email protected] Mardoniusz Maćkowiak +48 605 959 539 +48 22 440 14 40 [email protected] Contact for institutional investors and analysts Piotr Owdziej +48 697 612 913 +48 22 440 14 40 [email protected] Information about Mabion S.A. Mabion S.A. (WSE:MAB) is a publicly traded Polish biopharmaceutical company, founded in 2007, which underwent a transformatio n in 2023–2024 into a biologics -focused CDMO (Contract Development and Manufacturing Organization) offering an integrated service portfolio. Mabion specializes in small to mid -sized projects at various stages of development – from early-stage development of stable cell lines to commercial manufacturing. Mabion’s core competencies include monoclonal antibody development technologies, recombinant protein production (using mammalian and insect cell expression systems), advanced analytics, and manufacturing of Drug Substance. The company operates in compliance with globally recognized quality standards, including GMP, GCP, and ISO. Mabion employs over 200 highly qualified professionals, including scientists, engineers and experts in quality, manufacturing and analytical development for biologics. Headquartered in the center of Europe, Mabion operates in Poland – an EU member state – providing access to highly regulated markets. The company's mission is to be a trusted global partner for the development and manufacturing of biologic medicines. Mabion is a public company listed on the Warsaw Stock Exchange. More information: www.mabion.eu

The release as fetched from its publisher. mabion.eu ↗